

DAFTAR PUSTAKA

- Agúndez, J.A., García-Martín, E., Martínez, C., 2009. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? *Expert. Opin. Drug. Metab. Toxicol.* 5(6):607–620. <https://doi.org/10.1517/17425250902970998>.
- Andersson, T., Alfredsson, L., Källberg, H., Zdravkovic, S., Ahlbom, A., 2005. Calculating measures of biological interaction. *Eur. J. Epidemiol.* 20(7):575–579. <https://doi.org/10.1007/s10654-005-7835-x>.
- Artana, I.G.N.B., Artini, I.G.A., Rai, I.B.N., Wiryanthini, I.A.D., 2020. Hepatic Injury and Glutathione s-transferase Deletion Related to Antituberculosis Use: An Observational Study in Balinese Population, Indonesia. *Open Access Maced. J. Med. Sci.* 8(B):334–338. <https://doi.org/10.3889/oamjms.2020.4435>.
- Bhala, N., Baigent, C., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J.A., Bombardier, C., Cannon, C., Farkouh, M.E., FitzGerald, G.A., Goss, P., Halls, H., Hawk, E., Hawkey, C., Hennekens, C., Hochberg, M., Holland, L.E., Kearney, P.M., Laine, L., Lanus, A., Lance, P., Laupacis, A., Oates, J., Patrono, C., Schnitzer, T.J., Solomon, S., Tugwell, P., Wilson, K., Wittes, J., Adelowo, O., Aisen, P., Al-Quorain, A., Altman, R., Bakris, G., Baumgartner, H., Bresee, C., Carducci, M., Chang, D.M., Chou, C.T., Clegg, D., Cudkowicz, M., Doody, L., Miedany, Y.E., Falandry, C., Farley, J., Ford, L., Garcia-Losa, M., Gonzalez-Ortiz, M., Haghghi, M., Hala, M., Iwama, T., Jajic, Z., Kerr, D., Kim, H.S., Kohne, C., Koo, B.K., Martin, B., Meinert, C., Muller, N., Myklebust, G., Neustadt, D., Omdal, R., Ozgocmen, S., Papas, A., Patrignani, P., Pelliccia, F., Roy, V., Schlegelmilch, I., Umar, A., Wahlstrom, O., Wollheim, F., Yocum, S., Zhang, X.Y., Hall, E., McGettigan, P., Midgley, R., Moore, R.A., Philipson, R., Curtis, S., Reicin, A., Bond, J., Moore, A., Essex, M., Fabule, J., Morrison, B., Tive, L., Davies, K., Yau, F., 2013. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 382(9894):769–779. [https://doi.org/10.1016/s0140-6736\(13\)60900-9](https://doi.org/10.1016/s0140-6736(13)60900-9).
- Bhattacharyya, A., Chattopadhyay, R., Mitra, S., Crowe, S.E., 2014. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. *Physiol. Rev.* 94(2):329–354.
- Blanco, G., Martínez, C., Ladero, J.M., Garcia-Martin, E., Taxonera, C., Gamito, F.G., Diaz-Rubio, M., Agundez, J.A.G., 2008. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. *Pharmacogenet. Genom.* 18(1):37–43. <https://doi.org/10.1097/fpc.0b013e3282f305a9>.
- Braver, M.W.D., Zhang, Y., Venkataraman, H., Vermeulen, N.P.E.,
Commandeur, J.N.M., 2016. Simulation of interindividual differences in inactivation of reactive para -benzoquinone imine metabolites of

- diclofenac by glutathione S -transferases in human liver cytosol. *Toxicol. Lett.* 255:52–62. <https://doi.org/10.1016/j.toxlet.2016.05.015>.
- Carbonell, N., Verstuyft, C., Massard, J., Letierce, A., Cellier, C., Deforges, L., Saliba, F., Delchier, J.C., Becquemont, L., 2010. CYP2C9*3 Loss-of-Function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. *Clin. Pharmacol. Ther.* 87(6):693–698. <https://doi.org/10.1038/clpt.2010.33>.
- Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., Sturkenboom, M., Perez-Gutthann, S., 2012. Individual NSAIDs and upper gastrointestinal complications. *Drug Saf.* 35(12):1127–1146. <https://doi.org/10.1007/bf03261999>.
- Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. *Am J Health Syst Pharm.* 2006 Oct 01;63(19):1837-51.
- Chaiamnuay, S., Allison, J.J., Curtis, J.R., 2006. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. *Am. J. Health Syst. Pharm.* 63(19):1837–1851.
- Chi, T.-Y., Zhu, H.-M., Zhang, M., 2018. Risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gastrointestinal bleeding resulting on people over 60 years old in Beijing. *Medicine* 97(18):e0665. <https://doi.org/10.1097/md.0000000000010665>.
- Dadbinpour, A., Sheikha, M.H., Darbouy, M., Afkhami-Ardekani, M., 2013. Investigating GSTT1 and GSTM1 null genotype as the risk factor of diabetes type 2 retinopathy. *J. Diabetes Metab. Disord.* 12(1). <https://doi.org/10.1186/2251-6581-12-48>.
- Dantu, S.V., Albright, J., 2024. Clopidogrel and Pharmacogenetics: Rethinking Perioperative Antiplatelet Management. *ACS Case Reviews in Surgery.* 4(7):1–5.
- Estany-Gestal, A., Salgado-Barreira, A., Sánchez-Diz, P., Figueiras, A., 2011. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs. *Pharmacogenet. Genom.* 21(7):357–364. <https://doi.org/10.1097/fpc.0b013e328346d2bb>.
- Figueiras, A., Estany-Gestal, A., Aguirre, C., Ruiz, B., Vidal, X., Carvajal, A., Salado, I., Salgado-Barreira, A., Rodella, L., Moretti, U., Ibáñez, L., 2016. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding. *Pharmacogenet. Genom.* 26(2):66–73. <https://doi.org/10.1097/fpc.0000000000000186>.
- Fleiss, J.L., Levin, B., Paik, M.C., 2003. *Statistical methods for rates and proportions. Wiley series in probability and statistics.* <https://doi.org/10.1002/0471445428>.
- Forgerini, M., Lucchetta, R.C., Urbano, G., De Nadai, T.R., De Carvalho Mastroianni, P., 2020. Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review. *Pharmacogenomics J.* 21(1):20–36. <https://doi.org/10.1038/s41397-020-00185-6>.
- Forgerini, M., Urbano, G., De Nadai, T.R., Batah, S.S., Fabro, A.T., De Carvalho Mastroianni, P., 2021. Genetic variants in PTGS1 and NOS3 genes increase

- the risk of upper gastrointestinal bleeding: a Case–Control study. *Front. Pharmacol.* 12. <https://doi.org/10.3389/fphar.2021.671835>.
- Forgerini, M., Urbano, G., De Nadai, T.R., Batah, S.S., Fabro, A.T., De Carvalho Mastroianni, P., 2023. The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study. *J. Pharm. Pharm. Sci.*, 26. <https://doi.org/10.3389/jpps.2023.11136>.
- Ghorbel, R., Salah, G.B., Ghorbel, R., Mahmoud, A.B., Chamkha, I., Mkaouar-Rebai, E., Ammar-Keskes, L., Fakhfakh, F., 2017. Do GSTM1 and GSTT1 polymorphisms influence the risk of developing mitochondrial diseases in a Tunisian population? *Environ Sci and Pollut Res.* 25(6): 5779–5787. <https://doi.org/10.1007/s11356-017-0775-7>.
- Ghosh, R., Alajbegovic, A., Gomes, A.V., 2015. NSAIDs and cardiovascular Diseases: Role of reactive oxygen Species. *Oxid. Med. Cell. Longev.* 2015:1–25. <https://doi.org/10.1155/2015/536962>.
- Grosser, T., Theken, K.N., FitzGerald, G.A., 2017. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. *Clin. Pharmacol. Ther.* 102(4):611–622. <https://doi.org/10.1002/cpt.794>.
- Gundling, F., Harms, R.T., Schiefke, I., Schepp, W., Mössner, J., Teich, N., 2008. Self assessment of warning symptoms in upper gastrointestinal bleeding. *Dtsch. Ärztebl. Int.* <https://doi.org/10.3238/arztebl.2008.0073>.
- Handa, Y., Fukushima, S., Yo, S., Osawa, M., Murao, T., Handa, O., Matsumoto, H., Umegaki, E., Sakakibara, T., Shiotani, A., 2021. A novel gene associated with small bowel bleeding in patients taking low-dose aspirin. *Dig. Liver Dis.* 53(7):841–845. <https://doi.org/10.1016/j.dld.2021.04.038>
- Hawkey, C.J., 2003. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. *Gut* 52(4):600–608. <https://doi.org/10.1136/gut.52.4.600>.
- Hirota, T., Eguchi, S., Ieiri, I., 2013. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. *Drug Metab. Pharmacokinet.* 28(1):28–37. <https://doi.org/10.2133/dmpk.dmpk-12-rv-085>.
- Hosmer, D.W., Lemeshow, S., 1992. Confidence interval estimation of interaction. *Epidemiol.* 3(5):452–456. <https://doi.org/10.1097/00001648-199209000-00012>.
- Huang, J.Q., Sridhar, S., Hunt, R.H., 2002. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet* 359(9300):14–22.
- Ikawati, Z., Askitosari, T., Hakim, L., Tucci, J., Mitchell, J., 2015. Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia. *Curr. Pharmacogenomics Pers. Med.* 12(4):236–239. <https://doi.org/10.2174/1875692113666150410214416>.
- Ingelman-Sundberg, M., Sim, S.C., Gomez, A., Rodriguez-Antona, C., 2007. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. *Pharmacol. Therapeut.* 116(3): 496–526.

- Jennings, D.L., Truby, L.K., Littlefield, A.J., Ciolek, A.M., Marshall, D., Jain, R., Topkara, V.K., 2021. Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. *Int. J. Artif. Organs.* 44(12):965–971. <https://doi.org/10.1177/03913988211013366>.
- Jin, B., Wan, S., Boah, M., Yang, J., Ma, W., Lv, M., Li, H., Wang, K., 2020. GSTM1 and GSTT1 Null Genotype Polymorphisms and Susceptibility to Arsenic Poisoning: a Meta-analysis. *Biol Trace Elem Res.* 199(6): 2085–2095. <https://doi.org/10.1007/s12011-020-02325-2>.
- John, A., Amiri, L., Shafarin, J., Howarth, F.C., Raza, H., 2021. Effect of aspirin on mitochondrial dysfunction and stress in the pancreas and heart of Goto-Kakizaki diabetic rats. *Life* 11(9):902. <https://doi.org/10.3390/life11090902>.
- Kathuria, A., Roosan, M., Sharma, A., 2021. CYP2C9 Polymorphism and Use of Oral Nonsteroidal Anti-Inflammatory Drugs. *US Pharmacist* 54(3):23–30.
- Kementerian Kesehatan Republik Indonesia, 2013. Laporan hasil Riset Kesehatan Dasar Indonesia (Riskesdas) tahun 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.
- Kirchheiner, J., Brockmoller, J., 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. *Clin. Pharmacol. Ther.* 77(1):1–16.
- Krasniqi, V., Dimovski, A., Domjanović, I.K., Bilić, I., Božina, N., 2016. How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. *Arh. Hig. Rada Toksikol.* 67(1):1–8. <https://doi.org/10.1515/aiht-2016-67-2754>.
- Laine, L., 2001. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. *Gastroenterology* 120(3):594–606. <https://doi.org/10.1053/gast.2001.21907>.
- Laine, L., Peterson W.L., 1994. Bleeding peptic ulcer. *N. Engl. J. Med.* 331:717–727.
- Lanas, A., Chan, F.K.L., 2017. Peptic ulcer disease. *Lancet* 390(10094):613–624. [https://doi.org/10.1016/s0140-6736\(16\)32404-7](https://doi.org/10.1016/s0140-6736(16)32404-7).
- Lanas, A., Hunt, R., 2006. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. *Ann. Med.* 38(6):415–428.
- Langman, M.J.S., 2001. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? *Pharmacoepidemiol. Drug Saf.* 10(1):13–19. <https://doi.org/10.1002/pds.561>.
- Lao, X., Peng, Q., Lu, Y., Li, S., Qin, X., Chen, Z., Chen, J., 2014. Glutathione S-transferase gene GSTM1, gene-gene interaction, and gastric cancer susceptibility: evidence from an updated meta-analysis. *Cancer Cell Int.* 14(1). <https://doi.org/10.1186/s12935-014-0127-3>.
- Laporte, J.-R., Ibáñez, L., Vidal, X., Vendrell, L., Leone, R., 2004. Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs. *Drug Saf.* 27(6):411–420.
- Lee, M., Kim, M., Cha, J.M., 2025. Risk of Lower Gastrointestinal Bleeding in Nonsteroidal Anti-inflammatory Drug (NSAID) and Proton Pump

- Inhibitor Users Compared with NSAID-Only Users: A Common Data Model Analysis. *Gut Liver*. <https://doi.org/10.5009/gnl240247>.
- Li, S., Lang, G., Zhang, Y., Yu, K., Shao, Z., Zhang, Q., 2018. Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer. *Cancer Med*. 7(9): 4202–4207. <https://doi.org/10.1002/cam4.1567>.
- Macías, Y., Tabales, J.G., García-Martín, E., Agúndez, J.A.G., 2020. An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. *Expert Opin Drug Metab. Toxicol*. 16(4):319–332. <https://doi.org/10.1080/17425255.2020.1744563>.
- Mallah, N., Zapata-Cachafeiro, M., Aguirre, C., Ibarra-García, E., Palacios-Zabalza, I., Macías-García, F., Piñeiro-Lamas, M., Ibáñez, L., Vidal, X., Vendrell, L., Martín-Arias, L., Sáinz-Gil, M., Velasco-González, V., Bacariza-Cortiñas, M., Salgado, A., Estany-Gestal, A., Figueiras, A., 2022. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study. *Ann. Med*. 54(1):379–392. <https://doi.org/10.1080/07853890.2021.2016940>.
- Martínez, C., Blanco, G., Ladero, J.M., García-Martín, E., Taxonera, C., Gamito, F.G., Diaz-Rubio, M., Agúndez, J. a G., 2004. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. *Br. J. Pharmacol* 141(2):205–208.
- Massó-González, E.L., Patrignani, P., Tacconelli, S., Rodríguez, L. a. G., 2010. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. *Arthritis Rheum*. 62(6):1592–1601.
- McEvoy, L., Carr, D.F., 2021. Pharmacogenomics of NSAID-Induced upper gastrointestinal toxicity. *Front. Pharmacol*. 12. <https://doi.org/10.3389/fphar.2021.684162>.
- Mehler, P.S., Brown, C., 2015. Anorexia nervosa – medical complications. *J. Eat. Disord*. 3(1). <https://doi.org/10.1186/s40337-015-0040-8>.
- Miners, J.O., Birkett, D.J., 1998. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *Br. J. Clin. Pharmacol*. 45:525–538.
- Nagata, N., Niikura, R., Sekine, K., Sakurai, T., Shimbo, T., Kishida, Y., Tanaka, S., Aoki, T., Okubo, H., Watanabe, K., Yokoi, C., Akiyama, J., Yanase, M., Mizokami, M., Uemura, N., 2015. Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: A case-control study. *J. Gastroenterol. Hepatol*. 30(2):292–298. <https://doi.org/10.1111/jgh.12805>.
- Nakanishi, G., Pita-Oliveira, M., Bertagnolli, L.S., Torres-Loureiro, S., Scudeler, M.M., Cirino, H.S., Chaves, M.L., Miwa, B. & Rodrigues-Soares, F., 2022. Worldwide Systematic Review of GSTM1 and GSTT1 Null Genotypes by continent, Ethnicity, and therapeutic Area. *OMICS J. Integr. Biol*. 26(10): 528–541. <https://doi.org/10.1089/omi.2022.0090>.
- Negovan, A., Iancu, M., Moldovan, V., Mocan, S., Banescu, C., 2017. The Interaction between GSTT1, GSTM1, and GSTP1 Ile105Val Gene Polymorphisms and Environmental Risk Factors in Premalignant Gastric

- Lesions Risk. *BioMed Res. Int.* 2017:1–9. <https://doi.org/10.1155/2017/7365080>.
- Nehlig, A., 2022. Effects of Coffee on the Gastro-Intestinal Tract: A Narrative Review and Literature update. *Nutrients.* 14(2):399. <https://doi.org/10.3390/nu14020399>
- Padma, V., Gurukul, S.M.K., Vignesh, Javid, S.M., 2014. Gastric Mucosal Changes in Type 2 Diabetic Patients. *World J. Med. Sci.* 10(2):129-134. DOI: 10.5829/idosi.wjms.2014.10.2.8294.
- Pallapolu, P., Kuna, L., Chakraborty, A., Javed, G., Khan, A.A., 2024. Association of CYP3A4, GSTT1 and GSTM1 Gene Polymorphisms in early prediction of Gastritis in Choleric Temperament as per Unani Philosophy in Indian population. *Res. J. Pharm. Technol.* 2804–2812. <https://doi.org/10.52711/0974-360x.2024.00440>.
- Palli, D., Saieva, C., Gemma, S., Masala, G., Gomez-Miguel, M.J., Luzzi, I., D’Errico, M., Matullo, G., Ozzola, G., Manetti, R., Nesi, G., Sera, F., Zanna, I., Dogliotti, E., Testai, E., 2005. GSTT1 and GSTM1 gene polymorphisms and gastric cancer in a high-risk italian population. *Int. J. Cancer* 115(2):284–289. <https://doi.org/10.1002/ijc.20864>.
- Pilotto, A., Seripa, D., Franceschi, M., Scarcelli, C., Colaizzo, D., Grandone, E., Niro, V., Andriulli, A., Leandro, G., Di Mario, F., Dallapiccola, B., 2007. Genetic susceptibility to nonsteroidal Anti-Inflammatory Drug–Related gastroduodenal bleeding: Role of Cytochrome P450 2C9 Polymorphisms. *Gastroenterology* 133(2):465–471.
- Pilotto, A., Franceschi, M., Vitale, D.F., Zaninelli, A., Masotti, G., Rengo, F., 2005. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. *Aliment. Pharmacol. Ther.* 22(2):147–155.
- Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K., Breckenridge, A.M., 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 329(7456):15–19.
- Prayuni, K., Razari, I., Yuliwulandari, R., 2019. Glutathione S-transferase M1 and T1 null allele frequencies among Indonesian ethnics toward improved disease risk assessment. *Environ. Toxicol. Pharmacol.* 65:14–17. <https://doi.org/10.1016/j.etap.2018.10.008>.
- Prysyazhnyuk, V., Sydoruk, L., Sydoruk, R., Prysyazhniuk, I., Bobkovych, K., Buzdugan, I., Dzuryak, V., Prysyazhnyuk, P., 2021. Glutathione-S-transferases genes-promising predictors of hepatic dysfunction. *World J. Hepatol.* 13(6):620–633. <https://doi.org/10.4254/wjh.v13.i6.620>.
- Ratna, M.G., Nugrahaningsih, D.A.A., Sholikhah, E.N., Dwianingsih, E.K., Malueka, R.G., 2020. The association between PON1 and GSTM1 genetic variation with methylation of p16 gene promoter among Javanese farmers exposed to pesticides at Magelang Regency, Central Java, Indonesia. *Heliyon* 6(5):e03993. <https://doi.org/10.1016/j.heliyon.2020.e03993>.
- Rodriguez, S., Gaunt, T.R., Day, I.N.M., 2009. Hardy-Weinberg Equilibrium Testing of biological ascertainment for Mendelian randomization studies. *Am. J. Epidemiol.* 169(4):505–514.

- Rodríguez, L. a. G., Martín-Pérez, M., Hennekens, C.H., Rothwell, P.M., Lanas, A., 2016. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. *PLoS ONE* 11(8):e0160046. <https://doi.org/10.1371/journal.pone.0160046>.
- Sato, Y., Yoshihisa, A., Nozaki, Y., Ohara, H., Sugawara, Y., Abe, S., Misaka, T., Sato, T., Oikawa, M., Kobayashi, A., Yamaki, T., Nakazato, K., Takeishi, Y., 2023. Geriatric Nutritional Risk Index predicts bleeding event in patients with heart failure. *ESC Heart Fail.* 11(2):702–708. <https://doi.org/10.1002/ehf2.14631>.
- Schjerning Olsen, A.M., Gislason, G.H., McGettigan, P., Fosbøl, E., Sørensen, R., Hansen, M.L., Køber, L., Torp-Pedersen, C., Lamberts, M., 2015. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. *JAMA* 313(8):805.
- Shiotani, A., Murao, T., Fujita, Y., Fujimura, Y., Sakakibara, T., Nishio, K., Haruma, K., 2013. Novel single nucleotide polymorphism markers for low dose Aspirin-Associated small bowel bleeding. *PLoS ONE* 8(12):e84244.
- Sidhu, R., Brunt, L.K., Morley, S.R., Sanders, D.S., McAlindon, M.E., 2010. Undisclosed use of nonsteroidal Anti-Inflammatory drugs may underlie Small-Bowel injury observed by capsule endoscopy. *Clin. Gastroenterol. Hepatol.* 8(11):992–995.
- Smecuol, E., Sanchez, M.I.P., Suarez, A., Argonz, J.E., Sugai, E., Vazquez, H., Litwin, N., Piazuelo, E., Meddings, J.B., Bai, J.C., Lanas, A., 2009. Low-Dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. *Clin. Gastroenterol. Hepatol.* 7(5):524–529. <https://doi.org/10.1016/j.cgh.2008.12.019>.
- Strate, L.L., Joshi, A.D., Singh, P., Piawah, S., Boylan, M.R., Chan, A.T., 2017. Obesity increases the risk of gastrointestinal bleeding in men. *Gastroenterology* 152(5):945. [https://doi.org/10.1016/s0016-5085\(17\)33216-x](https://doi.org/10.1016/s0016-5085(17)33216-x).
- Suriapranata, I.M., Tjong, W.Y., Wang, T., Utama, A., Raharjo, S.B., Yuniadi, Y., Tai, S.S., 2011. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. *BMC Med. Genet.* 12(1). <https://doi.org/10.1186/1471-2350-12-80>.
- Szeto, C.-C., Sugano, K., Wang, J.-G., Fujimoto, K., Whittle, S., Modi, G.K., Chen, C.-H., Park, J.-B., Tam, L.-S., Vareesangthip, K., Tsoi, K.K.F., Chan, F.K.L., 2020. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. *Gut* 69(4):617–629. <https://doi.org/10.1136/gutjnl-2019-319300>.
- Tai, F.W.D., McAlindon, M.E., 2021. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. *Clin. Med.* 21(2):131–134. <https://doi.org/10.7861/clinmed.2021-0039>.
- Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C.P., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., Holm, L., Lindh, J.D., Rane, A., Wadelius, M., Deloukas, P., 2009. A Genome-Wide

- Association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of Warfarin dose. *PLoS Genet.* 5(3): e1000433.
- Tarone, R.E., Blot, W.J., McLaughlin, J.K., 2004. Nonselective nonaspirin Nonsteroidal Anti-Inflammatory Drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. *Am. J. Ther.* 11(1):17–25.
- Theken, K.N., Lee, C.R., Gong, L., Caudle, K.E., Formea, C.M., Gaedigk, A., Klein, T.E., Agúndez, J.A.G., Grosser, T., 2020. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal Anti-Inflammatory drugs. *Clin. Pharmacol. Ther.* 108(2):191–200. <https://doi.org/10.1002/cpt.1830>.
- Thorn, C.F., Ji, Y., Weinshilboum, R.M., Altman, R.B., Klein, T.E., 2012. PharmGKB summary. *Pharmacogenet. Genom.* 22(8):646–651. <https://doi.org/10.1097/fpc.0b013e3283527c02>.
- Tuba, S., Ikawati, Z., Mustofa, 2021. The frequencies of allele distribution of CYP2C9 and CYP2C19 gene polymorphisms in healthy Papuan population, Indonesia. *CMUJ Nat. Sci.* 20(3). <https://doi.org/10.12982/cmujns.2021.066>.
- Van Lieshout, E.M., Tiemessen, D.M., Roelofs, H.M., Peters, W.H., 1998. Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. *Biochim. Biophys. Acta (BBA) - General Subjects* 1381(3):305–311. [https://doi.org/10.1016/s0304-4165\(98\)00042-7](https://doi.org/10.1016/s0304-4165(98)00042-7).
- Walker, L.A., Zambraski, E.J., Williams, R.F., 2017. Widespread use of prescription nonsteroidal Anti-Inflammatory drugs among U.S. army active duty soldiers. *Mil. Med.* 182(3):e1709–e1712. <https://doi.org/10.7205/milmed-d-16-00183>.
- Wilkins, T., Wheeler, B., Carpenter, M., 2020. Upper gastrointestinal bleeding in adults: Evaluation and management. *Am. Fam. Physician* 101(5):294–300. <https://europepmc.org/article/MED/32109037>.
- Wolfe, M.M., Lichtenstein, D.R., Singh, G., 1999. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N. Engl. J. Med.* 340(24):1888–1899. <https://doi.org/10.1056/nejm199906173402407>.
- You, D., Lu, N., Duan, D., Li, H., Xing, W., 2016. The Association between GSTM1, GSTT1 Genetic Variants and Gastric Carcinoma Susceptibility in Chinese: A Systematic Review Article. *Iran. J. Public Health* 45(9):1103–1117.
- Zhou, Y., Boudreau, D.M., Freedman, A.N., 2013. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. *Pharmacoepidemiol. Drug Saf.* 23(1):43–50.
- Zhou, S.-F., Di, Y.M., Chan, E., Du, Y.-M., Chow, V., Xue, C., Lai, X., Wang, J.-C., Li, C., Tian, M., Duan, W., 2008. Clinical pharmacogenetics and potential application in personalized medicine. *Curr. Drug Metab.* 9(8):738–784. <https://doi.org/10.2174/138920008786049302>.
- Zhou, Y., Nevosadová, L., Eliasson, E., Lauschke, V.M., 2023. Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. *Hum. Genomics* 17(1). <https://doi.org/10.1186/s40246-023-00461-z>.